These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 32554740)

  • 1. Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.
    van den Elsen SH; Sturkenboom MG; Akkerman O; Barkane L; Bruchfeld J; Eather G; Heysell SK; Hurevich H; Kuksa L; Kunst H; Kuhlin J; Manika K; Moschos C; Mpagama SG; Muñoz Torrico M; Skrahina A; Sotgiu G; Tadolini M; Tiberi S; Volpato F; van der Werf TS; Wilson MR; Zúñiga J; Touw DJ; Migliori GB; Alffenaar JW
    BMJ Open; 2020 Jun; 10(6):e035350. PubMed ID: 32554740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
    Davies Forsman L; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar JW; Mansjö M; Hoffner S; Xu B; Schön T; Bruchfeld J
    BMJ Open; 2018 Oct; 8(9):e023899. PubMed ID: 30287613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes.
    Kang YA; Shim TS; Koh WJ; Lee SH; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Kim KC; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee HK; Heo E; Yim JJ
    Ann Am Thorac Soc; 2016 Mar; 13(3):364-70. PubMed ID: 26871879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring.
    Pai Mangalore R; Chai MG; Pope J; Lee SJ; Padiglione A; Diehl A; Roberts L; Sim K; Rawson-Harris P; Wicha S; Schneider HG; Peel TN; Jenney A; Ayton D; Peleg AY; Udy AA
    BMJ Open; 2024 Jul; 14(6):e083635. PubMed ID: 38951004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
    Koh WJ; Lee SH; Kang YA; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Chan Kim K; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee YS; Heo EY; Lee J; Ki YW; Shim TS; Yim JJ
    Am J Respir Crit Care Med; 2013 Oct; 188(7):858-64. PubMed ID: 23927582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
    Fox GJ; Nguyen CB; Nguyen TA; Tran PT; Marais BJ; Graham SM; Nguyen BH; Velen K; Dowdy DW; Mason P; Britton WJ; Behr MA; Benedetti A; Menzies D; Nguyen VN; Marks GB
    BMJ Open; 2020 Jan; 10(1):e033945. PubMed ID: 31900274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study.
    Ghimire S; Karki S; Maharjan B; Kosterink JGW; Touw DJ; van der Werf TS; Shrestha B; Alffenaar JW
    BMJ Open Respir Res; 2020 Aug; 7(1):. PubMed ID: 32796020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients.
    Li J; Burzynski JN; Lee YA; Berg D; Driver CR; Ridzon R; Munsiff SS
    Chest; 2004 Dec; 126(6):1770-6. PubMed ID: 15596672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring.
    Bolhuis MS; Akkerman OW; Sturkenboom MG; de Lange WC; van der Werf TS; Alffenaar JC
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S44-S45. PubMed ID: 28043603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India.
    Sharma R; Sharma SK; Singh BK; Mittal A; Kumar P
    Indian J Med Res; 2019 Jan; 149(1):62-66. PubMed ID: 31115377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
    Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
    BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring in the treatment of tuberculosis: an update.
    Alsultan A; Peloquin CA
    Drugs; 2014 Jun; 74(8):839-54. PubMed ID: 24846578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.